Legal & General Group Plc Buys Shares of 6,685 iRadimed Corporation $IRMD

Posted by Geri Gentry on Sep 9th, 2026

Legal & General Group Plc acquired a new position in iRadimed Corporation (NASDAQ:IRMD – Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 6,685 shares of the medical equipment provider’s stock, valued at approximately $639,000. Legal & General Group Plc owned approximately 0.05% of iRadimed as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of IRMD. Royal Bank of Canada grew its stake in shares of iRadimed by 14.7% during the 1st quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider’s stock valued at $1,354,000 after purchasing an additional 3,307 shares during the period. AQR Capital Management LLC lifted its stake in shares of iRadimed by 7.5% in the 1st quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider’s stock worth $831,000 after purchasing an additional 1,108 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of iRadimed by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after purchasing an additional 234 shares during the period. Jones Financial Companies Lllp boosted its holdings in shares of iRadimed by 8,568.5% in the first quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider’s stock worth $591,000 after buying an additional 11,139 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of iRadimed by 1.1% in the first quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider’s stock worth $8,889,000 after buying an additional 1,821 shares during the last quarter. 92.34% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Wall Street Zen lowered iRadimed from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings downgraded iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $120.00.

Get Our Latest Research Report on iRadimed

iRadimed Price Performance

IRMD stock opened at $84.40 on Wednesday. iRadimed Corporation has a 1-year low of $67.84 and a 1-year high of $107.90. The business has a 50 day simple moving average of $91.77 and a two-hundred day simple moving average of $93.37. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of 47.15 and a beta of 0.89.

iRadimed (NASDAQ:IRMD – Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. The company had revenue of $20.47 million for the quarter, compared to the consensus estimate of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. Sell-side analysts anticipate that iRadimed Corporation will post 1.98 EPS for the current fiscal year.

iRadimed Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, August 28th. Investors of record on Friday, August 14th were given a $0.20 dividend. The ex-dividend date was Friday, August 14th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is currently 44.69%.

Insider Buying and Selling

In other iRadimed news, Director Monty K. Allen sold 1,419 shares of iRadimed stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $86.41, for a total transaction of $122,615.79. Following the completion of the transaction, the director directly owned 19,581 shares of the company’s stock, valued at $1,691,994.21. The trade was a 6.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 34.60% of the stock is owned by insiders.

iRadimed Company Profile

(Free Report)

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.